Biora Therapeutics announced that the U.S. FDA has cleared the company’s Investigational New Drug application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIOR:
- Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- BIOR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
- Biora Therapeutics submits updated IND application for BT-600 ‘as planned’
- Biora Therapeutics Submits Updated IND Application for BT-600